



HAL
open science

Noninvasive vascular occlusion with HIFU for venous insufficiency treatment: preclinical feasibility experience in rabbits

N Barnat, A Grisey, B Lecuelle, J. Anquez, B Gerold, S. Yon, J.-F Aubry

► **To cite this version:**

N Barnat, A Grisey, B Lecuelle, J. Anquez, B Gerold, et al.. Noninvasive vascular occlusion with HIFU for venous insufficiency treatment: preclinical feasibility experience in rabbits. *Physics in Medicine and Biology*, 2019, 64 (2), pp.025003. 10.1088/1361-6560/aaf58d . hal-02403722

HAL Id: hal-02403722

<https://hal.science/hal-02403722>

Submitted on 11 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Noninvasive vascular occlusion with HIFU for venous insufficiency treatment:
2 preclinical feasibility experience in rabbits

3 AUTHORS/INSTITUTIONS:

4 N. Barnat^{1, 2, 3, 4}, A. Grisey⁴, B. Lecuelle⁵, J. Anquez⁴, B. Gerold⁴, S. Yon⁴, J.-F. Aubry^{1, 2, 3}

- 5 1- INSERM U979, Institut Langevin, Paris, France;
6 2- ESPCI Paris, PSL Research University, Institut Langevin, Paris, France;
7 3- CNRS UMR 7587, Institut Langevin, Paris, France;
8 4- Theraclion, Malakoff, France;
9 5- Ecole nationale vétérinaire d'Alfort, CRBM, Maisons-Alfort, France

10

11 Abstract

12 Venous insufficiency is a common disease arising when veins of the lower limb become
13 incompetent. A conventional surgical strategy consists in stripping the incompetent veins.
14 However, this treatment option is invasive and carries complication risks. In the present
15 study, we propose noninvasive high-intensity focused ultrasound (HIFU) to treat lower limbs
16 venous insufficiency, in particular incompetent perforating veins (mean diameter between 2-6
17 mm).

18 Sonication parameters were designed by numerical simulations using the k-Wave toolbox to
19 ensure continuous coagulation of a vein with a diameter superior or equal to 2 mm. The
20 selected ultrasound exposures were 4 seconds pulses in continuous wave mode. Two types
21 of sonication were studied: (1) fixed pulses and (2) moving pulses at constant speed (0.75
22 mm.s⁻¹) across the vein.

23 The potential of these exposures to thermally occlude veins were investigated in vivo on
24 rabbit saphenous veins. The impact of vein compression during ultrasonic exposure was also
25 investigated.

26 Fifteen rabbits were used in these trials. A total of 27 saphenous veins (mean diameter $2.0 \pm$
27 0.6 mm) were sonicated with a transducer operated at 3 MHz. After a mean 15 days follow-

28 up, rabbits were euthanized and venous samples were extracted and sent for histologic
29 assessment. Only samples with the vein within the HIFU lesion were considered for analysis.
30 Simulated thermal damage distribution demonstrated that fixed pulses and moving pulses
31 respectively placed every 1.5 and 0.5 mm along the vein and delivered at an acoustic power
32 of 85 W and for 4 seconds were able to induce continuous thermal damages along the vein
33 segments.

34 Experimentally, both treatment parameters (1) and (2) have proven effective to occlude veins
35 with a success rate of 82%. Occlusion was always observed when compression was applied.
36 Our results demonstrate that HIFU can durably and non-invasively occlude veins of
37 diameters comparable to human veins.

38 Keywords: HIFU; ultrasound; thermal occlusion; vascular occlusion; vein

39 Introduction

40 Venous insufficiency is a common medical condition arising when a high pressure is
41 transmitted from deep to superficial venous system of the lower limbs. High-pressure
42 transmission frequently occurs through retrograde flow. This elevated venous pressure
43 causes the vein to become tortuous and dilated over time. Besides the unsightly appearance
44 of varicosities, venous disease is associated with pain and clinical signs may vary from
45 asymptomatic telangiectasia to achy ulcer [1]. The strategy to treat venous disease consists
46 in ceasing reflux by eliminating the involved incompetent vein segment.

47 Conventional surgical techniques consist in removing the vein. The invasive nature of
48 surgery leads to the development of minimally invasive procedures such as radiofrequency
49 ablation [2] or endovenous laser ablation [3]. In both cases, after introducing a catheter into
50 the vein, thermal energy is delivered, in order to denature collagen and induce a shrinkage of
51 the vein [4,5].

52 Although these techniques proved their efficacy, they are not appropriate to treat all leg
53 veins. In case of incompetent perforating veins, thermal ablation is appropriate only for large
54 (>3.5 mm) perforators and may treat perforators only superficially [6]. Furthermore, treating

55 pathologic veins can be technically challenging and requires experienced physicians
56 especially for the insertion of the catheter in a deep or tortuous vein.

57 In this context, high-intensity focused ultrasound treatments (HIFU) could provide a non-
58 invasive alternative to occlude incompetent veins.

59 Previous studies have demonstrated HIFU occlusion in blood vessels of small diameters only
60 (range 0.5-1.5 mm) [7,8,17–21,9–16]. The occlusion of large vessels (≥ 2 mm) has not been
61 reported to the best of our knowledge. We demonstrate here on a rabbit model that HIFU can
62 occlude large veins (≥ 2 mm), paving the way for a clinical treatment of venous insufficiency
63 with focused ultrasound.


64 For this purpose, sonication strategies including placement and trajectory of pulses were first
65 identified by numerical simulations and then evaluated on an *in vivo* model of rabbit veins
66 (range: 1.1-3.7 mm).

67 Methods

68 Ultrasound equipment

69 Experiments were performed with the Echopulse® HIFU device (Theraclion, Malakoff,
70 France) used clinically for human breast fibroadenomas [22] and benign thyroid nodules [23]
71 treatments (Figure 1(a)). The system encompasses a treatment head mounted on an
72 articulated arm which includes a single element piezocomposite therapy transducer and a
73 linear confocal imaging probe for real-time monitoring of the treatment (Figure 1(b)). The
74 therapy transducer, operated at 3 MHz, has a spherical cap shape with a curvature radius of
75 38 mm and an outer diameter of 56 mm. The RF signal applied to the transducer comes from
76 a frequency generator (JJ&A Instruments, Model RFG-200T1) with an electric power ranging
77 from 10 to 215 W. The ultrasound imaging probe working at a frequency of 6.2 MHz
78 (Vermon, Tours, France) was connected to an Aixplorer® ultrasound system (SuperSonic
79 Imagine, Aix-en-Provence, France) to guide treatments with B-mode images. By
80 construction, the therapeutic focus is located within the imaging plane. A fluid-filled balloon

81 (EPack, Theraclion®, Malakoff, France) was fixed to the transducer to ensure acoustic
82 coupling between the transducer and the target. The coupling liquid was circulated and
83 cooled during all the procedure to avoid transducer overheating and skin burns. Cooling is
84 ensured by built-in Peltier modules (Figure 1 (a)). A dedicated software implemented in
85 MATLAB (MathWorks, Inc., Natick, Massachusetts, United States) was used to drive
86 sonications.



87

88 Figure 1: Ultrasound equipment: (a) Echopulse, (b) HIFU transducer.

89 Treatments simulation


90 Simulations were performed to adjust ultrasound exposures layout to adequately sonicate a
91 vein of 2 cm in length and 2 mm in diameter. Two types of pulses were studied: (1) fixed
92 pulses and (2) moving pulses at constant speed ($0.75 \text{ mm}\cdot\text{s}^{-1}$) along a line orthogonal to the
93 longitudinal axis of the vein. In both cases, we used 4-second sonications delivered in
94 continuous wave mode at an acoustic power of 85 W (typical power used in clinics and in our
95 experiments) and with the focus located at 15 mm under the skin. Acoustic pressure field,
96 temperature rise and, ultimately, thermal damages extent were simulated.

97 Geometrical model

98 The modelled HIFU transducer has the same geometry than the therapy transducer
99 described in the Ultrasound equipment section. The frame of reference of the transducer was
100 defined as follows: the origin corresponds to the HIFU transducer focus. X is the axis of the
101 imaging transducer and oriented along the left-to-right direction of the generated images. Z
102 denotes the main ultrasound propagation axis, pointing towards the subject anatomy. Y
103 results from the cross product of Z and X, for the frame (X, Y, Z) to be orthonormal and right-
104 handed.

105 In the simulations, the vein was considered as collapsed and the blood flow abolished. Thus,
106 the vein itself was not modelled. We assumed that the ultrasound beam propagates through
107 3 layers, from top to bottom: (1) the cooling liquid contained in the balloon fixed to the
108 transducer; (2) the skin and (3) the muscle. Skin was modelled as a 2-mm thick layer. For
109 illustration purposes, a 2D view of the geometrical model is shown in Figure 2.

110



111

112

Figure 2: Model used in the simulations

113 Acoustic simulation

114 Acoustic simulations were performed using the k-Wave toolbox 1.2 [24]. The toolbox solves
115 the system of coupled first-order partial differential equations comprising momentum
116 conservation, mass conservation and pressure-density relation.

117 To solve the system of coupled acoustic equations, k-Wave uses a k-space pseudospectral
118 method where spatial gradients are computed using the Fourier collocation spectral method
119 [24]. Although the mathematical approach used in k-Wave is efficient, the 3D simulation of
120 the HIFU beam is costly in terms of memory. In our case, at 3 MHz and considering a
121 domain of $60 \times 60 \times 46$ mm, the simulation of the nonlinear propagation up to the fifth
122 harmonic with the minimum of two points per wavelength requires a grid of 1.37×10^9 points.
123 Hence, to reduce memory requirements, we used a “layer by layer” approach [25]. The
124 computational grid is divided into finer and finer layers along the main propagation axis and
125 we simulated ultrasound propagation from the transducer to 3 mm beyond the focus. We
126 respectively used one layer for the cooling liquid, one layer for the skin and five layers for
127 muscle tissue. Nonlinearities were modeled up to the fifth harmonic in the widest layer.

128 The size of the smallest layer was $4 \times 4 \times 4$ mm (corresponding to $8 \times 8 \times 8$ wavelengths),
129 with a spatial grid step of $49.8 \mu\text{m}$. A perfectly matched layer was used to avoid reflections at
130 the boundaries of the domain.

131 The Courant-Friedrichs-Lewy (CFL) number was set to 0.5 resulting in a smallest time step
132 of 14.8 ns. The pressure acoustic source term was computed as:

$$p^2 = \frac{2P_{ac}\rho c_s}{S_{transducer}}$$

133 The cooling liquid, skin, fat and muscle tissue were modeled as homogenous media with the
134 acoustic properties listed in

135

136 Tissue properties were assumed to remain constant for the full procedure period. Variability
137 of parameters with temperature was neglected for all simulations.

138

	Cooling liquid [26]	Superficial tissue (skin...)[26]	Muscle [27]
Sound speed (m.s^{-1})	1495	1547	1587
Density (kg.m^{-3})	1000	1214	1041
Attenuation at 3 MHz [dB.cm^{-1}]	0	2.2	3.0
Acoustic non-linearity parameter	4.9	9.0	7.8

139 Table 1: Acoustic properties of tissues used for simulations.

140 Thermal simulation

141 Tissue heating was modeled using the Pennes's bioheat equation [28]. The equation was
142 solved in 3D using a first-order explicit Euler scheme in time and a centered scheme in
143 space.

144 The time step was 50 ms and the spatial step was 200 μm . The grid size was 38 \times 38 \times 29
145 mm.

146 The heat source term was computed as stated in [25]. The classic attenuation model
147 (absorption + scattering) was considered, and thermal rise was generated by the absorbing
148 component.

149 The tissue initial temperature was set to $T_0 = 39.5^\circ\text{C}$ which is the mean body temperature for
150 a rabbit [29] and Dirichlet boundary conditions were used with $T_{\text{boundaries}} = T_0$. We modelled
151 skin cooling as a heat flux at skin surface considering that the temperature of the cooling fluid
152 was 10°C (value achieved during experiments) and the heat transfer coefficient between skin
153 and liquid was set to $320 \text{ W.m}^2.\text{K}^{-1}$ based on previous experiments. To determine this value,
154 temperature of skin was first measured several times with a thermocouple slipped between
155 skin and the balloon in which circulated cooled liquid. Thereafter by assuming that heat flow
156 at skin is proportional to the difference of temperatures between skin and a characteristic
157 temperature of the cooling liquid, the value of $320 \text{ W.m}^2.\text{K}^{-1}$ has been assigned. As
158 experimentally, the cooling time between subsequent sonications was set to 15 seconds.

159 The tissue properties used in thermal simulations are listed in Table 2 and were assumed
 160 invariant with temperature in simulations.

	Muscle[30]
Specific heat capacity (J.kg ⁻¹ .K ⁻¹)	3600
Thermal conductivity (W.m ⁻¹ .K ⁻¹)	0.47
Perfusion (s ⁻¹)	0.018

161 Table 2: thermal properties of media used in thermal simulation.

162 Thermal damage

163 To achieve vessel sealing, sufficient thermal damage shall be induced to the vessel wall.

164 Modelling of vascular thermal damage [31] suggests that vessel thermal damage correlates
 165 with the denaturation of collagen fibrils, which begins at 62°C [32].

166 In this study, extent of thermal damage to vessels was evaluated based on a dedicated
 167 thermal damage model.

168 To assess the level of damage induced to vessels, we implemented the model described by
 169 Agah [31]. By considering denaturation of collagen as a first-order reaction, damage was
 170 modelled using a general Arrhenius equation:

$$\Omega(t) = \ln\left(\frac{c(0)}{c(\tau)}\right) = A_f \int_0^\tau \exp\left(\frac{-E_a}{RT(t)}\right) dt$$

171 Where:

172 $\Omega(t)$ is the damage parameter. $c(0)$, $c(\tau)$ are the concentrations of the undamaged
 173 molecules at the beginning and at time τ respectively. A_f is a coefficient of rate process
 174 (frequency factor), E_a the activation energy, R the universal gas constant, and T the
 175 temperature. A_f and E_a were set to $A_f = 5.6 \times 10^{63} \text{s}^{-1}$ and $E_a = 430 \text{kJ.mol}^{-1}$ according to
 176 [31].

177 Degree of vessel damage is appraised by $\Omega(t)$, where $\Omega(t) = 1$ defines the first noticeable
 178 irreversible damage and formally corresponds to the denaturation of 63% of the native
 179 proteins [31]. As we are looking for an extensive damage to the vein, we set the threshold
 180 for thermal damage to $\Omega(t) = 5$, which formally corresponds to the denaturation of 99% of
 181 the collagen.

182 Animals

183 All animal work was approved by the institutional ethics committee for animal experiments
184 (agreement number CE16/2016082512126208). Experiments were carried out according to
185 the guidelines of the French National Comity for animal trials C.N.R.E.E.A (*Comité national*
186 *de réflexion éthique sur l'expérimentation animale*). New-Zealand white rabbits (n=15), 5
187 males and 10 females, 2 to 4 months (3 ± 1) old and weighing 2.7 to 4.5 kg (3.5 ± 0.5), were
188 used for the experiments. HIFU exposures were applied on medial saphenous veins. Prior to
189 sonications, the animals were anesthetized intramuscularly with a mixture of Ketamine (0.33
190 mg/kg), Domitor (0.5 mg/kg) and Valium (0.17 mg/kg). They were then intubated with an
191 endotracheal tube and ventilated with isoflurane to be kept under anesthesia throughout the
192 procedure. The fur of their hind limbs was shaved with a hair trimmer and then carefully
193 depilated with a depilatory cream to ensure good acoustic coupling and prevent skin burns.

194 HIFU procedure


195 Before the procedure, the rabbit was placed on the table in supine position to access the
196 targeted vein. Ultrasonic gel (Polysonic Parker Laboratories, Inc., Fairfield, NJ) was applied
197 to the area to be treated to ensure appropriate coupling. B-mode ultrasound and color
198 Doppler imaging were used to position the focus on the vein.

199 27 medial saphenous veins (average diameter of 2 mm) were exposed to HIFU.

200 Blood flow is known to hamper thermal therapies by cooling down the vein wall [33–37].

201 Therefore, several configurations based on previous simulations were tested during the HIFU
202 treatments: (1) 5 veins were treated with multiple pulses (median 1.5 mm spacing) distributed
203 along the target vein (Figure 3A)); (2) 14 veins underwent the same treatment protocol than
204 the one used in configuration (1) but the hind limb was elevated to about 25 degrees from the
205 horizontal to diminish blood flow (Figure 3 B)); and (3) 8 veins were sonicated with moving
206 pulses ($0.75 \text{ mm}\cdot\text{s}^{-1}$ along a 3-mm line transecting the vein) (**Erreur ! Source du renvoi**
207 **introuvable.**) and were mechanically compressed by pressing a finger on the groin during
208 exposures to stop blood flow and minimize its heat sink effect. Rear limbs elevation empty

209 veins of their intraluminal blood and induce venous spasm (illustrated in **Erreur ! Source du**
 210 **renvoi introuvable.** for configurations (2) and (3)). The average diameter of the vein after
 211 proximal compression was of 1 mm. According to simulations, for configuration 3, the
 212 spacing between moving pulses was reduced to 0.5 mm to account for the smaller lesion
 213 size in the longitudinal direction (Figure 3C)
 214 Thus, the number of sonications was increased to sonicate the same length of 2 cm.



215
 216 Figure 3: Schema illustrating dispositions of HIFU exposures. A), B) and C) stand for
 217 configurations (1), (2) and (3) respectively.

218 For all cases, HIFU sonications were applied for 4 seconds and at an acoustic power of $83 \pm$
 219 10 W (obtained by multiplying electric power by the 70% efficiency of the transducer). The
 220 corresponding spatial-peak intensity (linear extrapolation from low power hydrophone
 221 measurement in water is 28 kW.cm^{-2} . A minimum time period of 15 s was set between two
 222 sonications to allow the skin to cool down. Experimental protocols are summarized in Table
 223 3.

Experimental protocol ID	1	2	3
Number of HIFU exposed veins	5	14	8
Sonication types	Fixed pulses 1.5 mm apart	Fixed pulses 1.5 mm apart	Linear track with sites 0.5 mm apart Hind limb elevated

		Hind limb elevated	Vein compressed
--	--	--------------------	-----------------

224 Table 3: Experimental conditions

225 **Histological protocol**

226 After the experiments, the rabbits were recovered from anesthesia and were monitored for at
 227 least 15 days after treatment, to assess the sustainability of the effects of HIFU exposures on
 228 veins. Animals were then euthanized by intravenous injection of Pentobarbital (1 mL/kg).

229 The day of euthanasia, the animals underwent a *post mortem* dissection and the targeted
 230 vessel was harvested. In some cases, the perivenous conjunctive tissue was adherent and
 231 the vein could not be separated. In such cases, the vein was sent for analysis with the
 232 attached perivenous tissue.

233 The proximal tip of each venous section was sutured, preserved in identified cassettes, fixed
 234 in 4% formalin and sent for histologic examination. Samples were then cross-sectioned into 3
 235 subsections and included in paraffin. 4- μ m slices were cut and stained with haematoxylin-
 236 eosin (HE) for evaluation. Each section was evaluated without knowledge of the detailed
 237 treatment status.

238 Excision of the proper vein segment is difficult since other veins branch in the vicinity of the
 239 target. Therefore, samples were taken into account only when a vein was present on the
 240 slide and was located within the HIFU lesion.

241 A venous sample from untreated region was also extracted and served as a control.


242 Changes were graded as: normal vein (0), reactive endothelium (1), myoendothelial
 243 proliferation (2), acute fibrinous thrombi (3) and thrombus organization (4).

244 **Results**

245 **Numerical model**

246 *Ultrasound pressure field*

247 Figure 4 shows the rms acoustic pressure field profile in the YZ plane simulated with the
248 “layer by layer” approach. Simulations were ran at 3 MHz and at an acoustic power of 85 W.




249

250 Figure 4: Simulated rms pressure field of the geometrical model in the YZ plane simulated.

251 Pressure is expressed in MPa. Yellow rectangles represent the limits of the subsequent
252 layers.

253 *Thermal damages*

254 Temperature elevation at the expected location of the upper vein wall (2 mm above the focal
255 point centered on the lower vein wall) is plotted on Figure 5 for configurations (2) and (3).



256

257 Figure 5: Simulated temperature elevation at the location of the vein wall during 4 s
 258 sonification followed by 15 s cooling for unitary fixed pulse (solid line) and moving pulse
 259 (dash line).

260 For unitary fixed and moving pulse, the extent of the coagulated zone as defined using the
 261 thermal damage model was 1.2 mm and 0.6 mm along the vein respectively and 1.8 mm and
 262 2.7 mm in the orthogonal direction to the vein respectively.

263 To induce homogeneous and extensive heating of a vein 2 cm in length and 2 mm in
 264 diameter, we considered: (1) for fixed pulses, 13 sonications with a spacing of 1.5 mm and
 265 (2) for moving pulses, 37 sonications moving along the cross sectional axis with a spacing of
 266 0.5 mm along the longitudinal axis of the vein.

267 Figure 6 and Figure 7 show the results of thermal damage distribution for such treatments:
 268 (1) 13 fixed pulses and (2) 37 moving pulses respectively. An iso-contour representing the
 269 area corresponding to denaturation of 99% of native proteins is displayed.

270 Distribution of thermal damage simulations are displayed using maximum intensity
 271 projections.

272

273 Figure 6: Maximum intensity projected damage map at the end of a treatment comprising
274 thirteen 4-s fixed pulses delivered 1.5 mm apart at an acoustic power of 85 W and with the
275 focus located at 15 mm under skin. Iso-contour corresponding to: the thermal damage where
276 99% of native proteins denature is displayed in black.

277

278 Figure 7: Projected damage map at the end of a treatment comprising 37 4-s pulses during
279 which the focus was moved at $0.75 \text{ mm}\cdot\text{s}^{-1}$. Sonications were delivered at an acoustic power
280 of 85 W, with a spacing of 0.5 mm and with the focus located at 15 mm under skin. Iso-
281 contour corresponding thermal damage where 99% of native proteins denature is displayed
282 in black.


283 To quantify the impact of the trajectory, attention has been given to the extent of the region
284 corresponding to protein denaturation.

285 Damaged zones in the XY plane of the vein for treatment layouts (1) and (2) are reported in
286 Table 4.

Treatments ID	Damaged zone	Lesion area
(1)	19.2 × 2.4 mm ²	42.8 mm ²
(2)	19.2 × 4.2 mm ²	72.0 mm ²

287 Table 4: Simulated results in terms of damaged areas for treatment plannings (1) and (2)

288 After HIFU exposures, vessel damage can be observed through vessel shrinkage as
289 illustrated in the following ultrasound image (Figure 8).



290

291 Figure 8: Acute vascular shrinkage following HIFU pulses

292 Histological findings

293 Clinical follow-up of the animals showed that recovery after HIFU treatments were well
294 tolerated. All animals survived until the day of euthanasia and no abnormal behavior was
295 noted postoperatively. All animals continued their normal pattern of feeding.

296 As mentioned in Histological protocol, only samples satisfying acceptance criterion were
297 considered in the study.


298 In total and excluding the control sample, 17 samples (63%) were taken into account in this
 299 study. Histological results are reported in Table 5.

Experimental protocol ID	1	2	3
Number of accepted samples	1	10	6
Sonication types	Fixed pulses 1.5 mm apart	Fixed pulses 1.5 mm apart Hind limb elevated	Linear track with sites 0.5 mm apart Hind limb elevated Vein compressed
Follow-up duration	15 days	15 days	13 days
Occlusion score	0 : 1/1	0 : 2/10 3 : 1/10 4 : 7/10	3 : 3/6 3 : 3/6

300 Table 5: Results of vessel occlusion for each batch

301 The follow-up duration indicated in Table 5 corresponds to the median value. It is however
 302 necessary to emphasize that follow-up duration extended from 7 days for the shortest one to
 303 19 days for the longest one due to the availability of the animal facility.

304 For all samples treated with fixed pulses and with a score superior or equal to 3, histological
 305 findings revealed a thrombo-vasculitis of the saphenous vein characterized by a transmural
 306 thickening and collapse of the lumen. Fibrinous thrombi were also present. These lesions are
 307 irreversible in nature or expected to be irreversible (as assessed by the histopathologist) for
 308 the samples with a follow-up duration inferior to 13 days. Lesions were expected to evolve
 309 towards the formation of large fibrotic scars incorporating saphenous veins. Figure 9 shows
 310 illustrative HE stained histologic cross sections.



311

312

313

314

Figure 9: HE sections (magnification 5x) of representative saphenous veins (green rectangles) showing a transmurular thickening and collapse of their lumens. The sections (a) and (b) respectively correspond to veins treated according to protocols (2) and (3).

315

316

317

318

319

The lesions observed on samples sonicated with moving pulses were histologically identical to those treated with fixed pulses. However, variability in the severity of the lesions was observed between samples. The majority (73%) of samples treated with fixed pulses showed a severe thrombo-vasculitis while lesions were evenly distributed between severe and moderate for samples sonicated with moving pulses.

320

Discussion

321

322

323

The feasibility of inducing sustainable vascular occlusion with HIFU thermal effects was demonstrated since histology reported 82% of vascular occlusion. Occlusion was successful in all cases where compression was applied.

324

325

Histological analysis systematically showed severe lesions for samples which underwent fixed point-by-point sonications and moderate lesions for half of the ones that were treated

326 by moving pulses. With moving pulses, the energy delivered is more spread and results in
327 less severe lesions.

328 However, vein samples that showed no occlusion were treated with fixed pulses. According
329 to simulations in the orthogonal direction to the vein diameter, coagulated zone after fixed
330 pulses is barely enough to cover the vein. Fixed pulses are effective when the vein wall is
331 completely encompassed in the lesion.

332 After fixed pulses, the coagulated zone is 2.4 mm in diameter and does not cover the whole
333 circumference of all targeted veins (diameter range between [1.1 – 3.7 mm]).

334 Conversely, moving pulses cover an area 1.8 times wider which reliably damage the whole
335 circumference of all the veins. However, treatment with moving pulses required nearly three
336 times more sonications than treatment with fixed pulses to treat a same vein segment.

337 The lack of symmetry observed in the figure 5 resulted from heat accumulation effect. As
338 sonications are delivered, thermal energy deposited by previous pulse is added to energy
339 deposition of current pulse. There is therefore an overlap in heat accumulation between
340 successive pulses.

341 Although temperature dependence of ultrasound parameters has been demonstrated
342 experimentally [38,39,48,49,40–47], constant acoustic parameters were used in the
343 simulation as done by other teams[50–53]

344 In this study, we did not investigate focus movement speeds higher than $0.75 \text{ mm}\cdot\text{s}^{-1}$ but
345 further work may be performed to assess the highest focus speed that can lead to both a fast
346 and an effective occlusion.

347 Considering the good correlation between simulations and histologic findings, the model
348 used to assess thermal damage in the vein, based on the denaturation of collagen, appears
349 to be consistent. This is supported by the study conducted by Fujiwara et al [54] where
350 vessel occlusion was observed when peak temperature of the insonated sample hit 98°C but
351 not at 47°C or 54°C .

352 Area corresponding to denaturation of 99% of native proteins correlates with the region
353 where temperature reached 85°C. This temperature is also the level recommended by
354 radiofrequency closure ablation to seal veins.

355 By heating homogeneously the intima to 85°C, we would mostly likely achieve total
356 coagulation of the vein wall.

357 In our study, the three occlusion-free samples correspond to treatments without
358 compression. We hypothesize that blood flow could have acted as a heat sink which
359 prevented the temperature elevation of the vein wall from reaching sufficient levels.
360 Compression should be considered for future clinical treatments as it helps to abolish blood
361 flow and to decrease lumen area.

362 The high temperature elevations obtained in the simulations indicate that in our study,
363 thermal effects of HIFU are expected to play a major role in our venous occlusions. Thermal
364 mechanism compares favorably to the use of purely mechanical occlusion effects as
365 reported by Hwang et al [55], which lead to a recanalization of the veins after the treatment.
366 Hwang et al [55] used pulsed HIFU exposures with a low duty cycle in synergy with
367 ultrasound contrast agent. The treatment was effective but could not maintain rabbit auricular
368 vein occlusion over 14 days. With similar pulsing regime (9 MPa peak rarefaction pressure,
369 1-Hz pulse repetition frequency), Zhou et al [15] demonstrated a sustainable occlusion with
370 mechanical effects of HIFU but only by injecting pro-inflammatory agents corresponding to
371 the detergents found in sclerosing agents [56].

372 Groups who used ultrasound alone reported a temporary occlusion that did not exceed one
373 week after treatments [8,54,57]. Notwithstanding that they have demonstrated occlusion in
374 small veins (<1.5 mm), no long-term occlusion was proved.

375 Our exposure ultrasound parameters without additives were sufficient to induce venous
376 closure. To date and to the best of our knowledge, no other study reported noninvasive
377 permanent occlusion on veins of similar size, with the use of thermal effects of HIFU.

378 Conclusion

379 In this study, two sonication strategies have been identified and evaluated in a rabbit model.

380 *In vivo* experiments have demonstrated that thermal ablation with HIFU can induce
381 permanent sealing of veins of up to 3.7 mm [1.1-3.7 mm] in diameter.

382 HIFU is thereby a promising alternative to treat incompetent perforating veins. The treatment
383 parameters used in this study provide insights for subsequent clinical trials.

384 Vein compression was identified as a key factor contributing to successful vascular occlusion
385 since it avoided the cooling effect of the blood flow.

386 Future work should demonstrate the ability to coagulate larger veins (in a larger animal
387 model) similar to the great saphenous vein and its tributaries.

388 References

389 [1] Alam M, Nguyen T H and Dover J S 2006 *Treatment of Leg Veins* (Elsevier)

390 [2] Goldman MP 2000 Closure of the great saphenous vein with endoluminal
391 radiofrequency thermal heating in combination with ambulatory phlebectomy:
392 preliminary 6-month follow-up *Dermatol Surg* **26** 452–6

393 [3] Navarro L, Min R J and Bone C 2001 Endovenous laser: a new minimally invasive
394 method of treatment for varicose veins-preliminary observations using an 810 nm
395 diode laser *Dermatol Surg* **27** 117–22

396 [4] Manfrini S, Gasbarro V, Danielsson G, Norgren L, Chandler J G, Lennox A F, Zarka Z
397 a. and Nicolaidis A N 2000 Endovenous management of saphenous vein reflux *J.*
398 *Vasc. Surg.* **32** 330–42

399 [5] Bergan J, Kumins N, Owens E and Sparks S 2002 Surgical end endovascular
400 treatment of lower extremity venous insufficiency *J. Vasc. Interv. Radiol.* **13** 563–8

401 [6] Dillavou E D, Harlander-Locke M, Labropoulos N, Elias S and Ozsvath K J 2016
402 Current state of the treatment of perforating veins *J. Vasc. Surg.* **4** 131–5

403 [7] Delon-Martin C, Vogt C, Chignier E, Guers C, Chapelon J Y and Cathignol D 1995

- 404 Venous thrombosis generation by means of high-intensity focused ultrasound
405 *Ultrasound Med. Biol* **21** 113–9
- 406 [8] Hynynen K, Chung A H, Colucci V and Jolesz F A 1996 Potential adverse effects of
407 high-intensity focused ultrasound exposure on blood vessels in vivo *Ultrasound Med.*
408 *Biol* **22** 193–201
- 409 [9] Hynynen K, V C, Chung A and Jolesz F 1996 Noninvasive arterial occlusion using
410 MRI-guided focused ultrasound *Ultrasound Med. Biol* **22** 1071–7
- 411 [10] Rivens I H, Rowland I J, Denbow M, Fisk N M, Ter Haar G R and Leach M O 1999
412 Vascular occlusion using focused ultrasound surgery for use in fetal medicine *Eur. J.*
413 *Ultrasound* **9** 89–97
- 414 [11] Denbow M L, Rivens I H, Rowland I J, Leach M O, Fisk N M and ter Haar G R 2000
415 Preclinical development of noninvasive vascular occlusion with focused ultrasonic
416 surgery for fetal therapy *J Obs. Gyneco* 387–92
- 417 [12] Ishikawa T, Okai T, Sasaki K, Umemura S ichiro, Fujiwara R, Kushima M, Ichihara M
418 and Ichizuka K 2003 Functional and histological changes in rat femoral arteries by
419 HIFU exposure *Ultrasound Med. Biol.* **29** 1471–7
- 420 [13] Fujiwara K, Takeuchi H, Itani K, Yoshinaka K, Sasaki A, Azuma T, Sakuma I,
421 Matsumoto Y, Medical H A, High T, Focused I and Aloka H 2011 Real time HIFU
422 beam imaging *Proc. 2001 Symp. Ultrason. Electron.* **32** 583–4
- 423 [14] Hwang J H, Tu J, Brayman A A, Matula T J and Crum L A 2006 Correlation between
424 inertial cavitation dose and endothelial cell damage in vivo *Ultrasound Med. Biol* **32**
425 1611–9
- 426 [15] Zhou Y, Zia J, Warren C, Starr F L, Brayman A A, Crum L A and Hwang J H 2011
427 Targeted long-term venous occlusion using pulsed high-intensity focused ultrasound
428 combined with a pro-inflammatory agent *Ultrasound Med Biol* **37** 1653–8
- 429 [16] Hwang J H, Brayman A A, Reidy M A, Matula T J, Kimmey M B and Crum L A 2005
430 Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast
431 agent treatments in vivo *Ultrasound Med. Biol* **31** 553–64

- 432 [17] Hwang J H, Zhou Y, Warren C, Brayman A A and Crum L A 2010 Targeted venous
433 occlusion using pulsed high-intensity focused ultrasound. *IEEE Trans. Biomed. Eng.*
434 **57** 37–40
- 435 [18] Ichizuka K, Ando S, Ichihara M, Ishikawa T, Uchiyama N, Sasaki K, Umemura S,
436 Matsuoka R, Sekizawa a, Okai T, Akabane T and Kushima M 2007 Application of
437 high-intensity focused ultrasound for umbilical artery occlusion in a rabbit model.
438 *Ultrasound Obstet. Gynecol.* **30** 47–51
- 439 [19] Ichiharan Mitsuyoshi, Sasaki K, Umemura S-I, Kushima M and Okai T 2007 Blood
440 flow occlusion via ultrasound image-guided high-intensity focused ultrasound and its
441 effect on tissue perfusion *Ultrasound Med. Biol* **33** 452–9
- 442 [20] Shaw C J, ter Haar G R, Rivens I H, Giussani D A and Lees C C 2014
443 Pathophysiological mechanisms of high-intensity focused ultrasound-mediated
444 vascular occlusion and relevance to non-invasive fetal surgery *J. R. Soc. Interface* **11**
- 445 [21] Zhang M, Fabiilli M L, Haworth K J, Fowlkes J B, Kripfgans O D, Roberts W W, Ives K
446 A and Carson P . 2010 In vivo investigation of acoustic droplet vaporization for
447 occlusion in canine kidney *Ultrasound* **36** 1691–703
- 448 [22] Kovatcheva R, Guglielmina J-N, Abehsera M, Boulanger L, Laurent N and Poncelet E
449 2015 Ultrasound-guided high-intensity focused ultrasound treatment of breast
450 fibroadenoma-a multicenter experience *J. Ther. Ultrasound* **3** 1
- 451 [23] Esnault O, Franc B, Leenhardt L, Rouxel A, Ménégau F and Lacoste F 2006 High-
452 Intensity Focused Ultrasound (Hifu) Treatment For Thyroid Nodules: Experimental and
453 First Clinical Studies *6th International Symposium on Therapeutic Ultrasound* vol 911
454 (AIP) pp 98–103
- 455 [24] Treeby B E and Cox B T 2010 k-Wave: MATLAB toolbox for the simulation and
456 reconstruction of photoacoustic wave fields *J. Biomed. Opt.* **15** 021314-1: 021314-12
- 457 [25] Grisey A, Yon S, Letort V and Lafitte P 2016 Simulation of high-intensity focused
458 ultrasound lesions in presence of boiling *J. Ther. Ultrasound* **4** 11
- 459 [26] Grisey A, Heidmann M, Letort V, Lafitte P and Yon S 2016 Influence of Skin and

- 460 Subcutaneous Tissue on High-Intensity Focused Ultrasound Beam: Experimental
461 Quantification and Numerical Modeling *Ultrasound Med. Biol* **42** 2457–65
- 462 [27] Duck F A 1990 Acoustic Properties of Tissue at Ultrasonic Frequencies *Phys. Prop.*
463 *Tissues* 73–135
- 464 [28] Pennes H H 1948 Analysis of tissue and arterial blood temperatures in the resting
465 human forearm. *J. Appl. Physiol.* **1** 93–122
- 466 [29] Kozma C, Macklin W, Cummins L M and Mauer R 1974 *The Biology of the Laboratory*
467 *Rabbit* ed S H Weisbroth, R E Flatt and A L Kraus (United States of America:
468 Academic Press Inc. (London) Ltd.)
- 469 [30] Duck F A 1990 Thermal Properties of Tissue *Phys. Prop. Tissues* 9–42
- 470 [31] Agah R, Pearce J A, Welch A J and Motamedi M 1994 Rate process model for arterial
471 tissue thermal damage: Implications on vessel photocoagulation *Lasers Surg. Med.* **15**
472 176–84
- 473 [32] Pankhurst K 1947 Incipient Shrinkage of Collagen and Gelatin *Nature* **159** 538
- 474 [33] Chent L, Ter Haart G, Hill C R, Dworkint M, Carnochant P, Young H and Benstedt J P
475 M 1993 Physics in Medicine & Biology Effect of blood perfusion on the ablation of
476 liver parenchyma with high-intensity focused ultrasound *Phys. Med. Biol* **38** 1661–73
- 477 [34] Goldberg S N, Stein M C, Gazelle G S, Sheiman R G, Kruskal J B and Clouse M E
478 1999 Percutaneous Radiofrequency Tissue Ablation: Optimization of Pulsed-
479 Radiofrequency Technique to Increase Coagulation Necrosis *J. Vasc. Interv. Radiol.*
480 907–16
- 481 [35] Heisterkamp J, Hillegersberg R van, Mulder P G ., Sinofsky E L and Ijzermans J N .
482 1997 Importance of eliminating portal flow to produce large intrahepatic lesions with
483 interstitial laser coagulation *Br. J. Surg.* 1245–8
- 484 [36] Patterson E J, Scudamore C H, Eng E, Owen D A, Nagy A G and Buczkowski A K
485 1998 Radiofrequency Ablation of Porcine Liver In Vivo Effects of Blood Flow and
486 Treatment Time on Lesion Size *Ann. Surg.* **227** 559–65
- 487 [37] Dorr L N and Hynynen K 1992 The effects of tissue heterogeneities and large blood

- 488 vessels on the thermal exposure induced by short high-power ultrasound pulses *Int. J.*
489 *Hyperth.* **8** 45–59
- 490 [38] Chato J . 1985 Measurement of thermal properties of biological materials *Heat Transf.*
491 *Med. Biol.* **1** 167–92
- 492 [39] Valvano J W, Cochran J R and Diller K R 1985 Thermal Conductivity and Diffusivity of
493 Biomaterials Measured with Self-Heated Thermistors *Int. J. Thermophys.* **6** 301–11
- 494 [40] Valvano J . and Chitsabesan B 1987 Thermal conductivity and diffusivity of arterial
495 wall and atherosclerotic plaque *Lasers Life Sci.* **1** 219–29
- 496 [41] Gammell P M, Le Croisette D H and Heyser R C 1979 Temperature and frequency
497 dependence of ultrasonic attenuation in selected tissues *Ultrasound Med. Biol.* **5** 269–
498 77
- 499 [42] Damianou C A, Sanghvi N T, Fry F J and Maass-Moreno R 1997 Dependence of
500 ultrasonic attenuation and absorption in dog soft tissues on temperature and thermal
501 dose *J. Acoust. Soc. Am.* **102** 628–34
- 502 [43] Gertner M R, Wilson B C and Sherar M D 1997 Ultrasound properties of liver tissue
503 during heating *Ultrasound Med. Biol.* **23** 1395–403
- 504 [44] Techavipoo U, Varghese T, Zagzebski J A, Stiles T and Frank G 2002 Temperature
505 Dependence of Ultrasonic Propagation Speed and Attenuation in Canine Tissue
506 *Ultrason. Imaging* **24** 246–60
- 507 [45] Zderic V, Keshavarzi A, Andrew M A, Vaezy S and Martin R W 2004 Attenuation of
508 porcine tissues in vivo after high-intensity ultrasound treatment *Ultrasound Med. Biol.*
509 **30** 61–6
- 510 [46] Choi M J, Guntur S R, Lee J M, Paeng D G, Lee K I L and Coleman A 2011 Changes
511 in ultrasonic properties of liver tissue in vitro during heating-cooling cycle concomitant
512 with thermal coagulation *Ultrasound Med. Biol.* **37** 2000–12
- 513 [47] Ghoshal G, Luchies A C, Blue J P and Oelze M L 2011 Temperature dependent
514 ultrasonic characterization of biological media *J. Acoust. Soc. Am.* **130** 2203–11
- 515 [48] Jackson E, Coussios C and Cleveland R 2014 Nonlinear acoustic properties of ex

516 vivo bovine liver and the effects of temperature and denaturation *Phys. Med. Biol* **59**
517 3223

518 [49] Bamber, J.C Hill C . 1979 Ultrasonic attenuation and propagation speed in mammalian
519 tissues as a function of temperature *Ultrasound Med. Biol.* **5** 149–57

520 [50] Constans C, Mateo P ., Tanter M and Aubry J . 2018 Potential impact of thermal
521 effects during ultrasonic neurostimulation: retrospective numerical estimation of
522 temperature elevation in seven rodent setups *Phys. Med. Biol.* **63**

523 [51] Eikelder H H ten;, Bosnacki D D, Elevelt A, Donato K, Tullio A D, Breuer B B, Wijk J
524 van;, Dijk E E van;, Modena D, Yeo S S Y and Grull H H 2016 Modelling the
525 temperature evolution of bone under high intensity focused ultrasound *Phys. Med.*
526 *Biol.* **61**

527 [52] Pinton G, Aubry J-F, Fink M and Tanter M 2011 Effects of nonlinear ultrasound
528 propagation on high intensity brain therapy *Med. Phys.* **38** 1207–16

529 [53] Meaney P M, Clarke R L, Ter Haar G R and Rivens I H 1998 A 3-D finite-element
530 model for computation of temperature profiles and regions of thermal damage during
531 focused ultrasound surgery exposures *Ultrasound Med. Biol.* **24** 1489–99

532 [54] Fujiwara R, Sasaki K, Ishikawa T, Suzuki M, Umemura S-I, Kushima M and Okai T
533 2002 Arterial Blood Flow Occlusion by High Intensity Focused Ultrasound and
534 Histologic Evaluation of Its Effect on Arteries and Surrounding Tissues *J Med*
535 *Ultrason.* **29** 85–90

536 [55] Hwang J H, Zhou Y, Warren C, Brayman A A and Crum L A 2010 Targeted venous
537 occlusion using pulsed high-intensity focused ultrasound *IEEE Trans Biomed Eng* **57**
538 37–40

539 [56] Loffroy R, Guiu B, Cercueil J-P and Krause D 2009 Endovascular Therapeutic
540 Embolisation: An Overview of Occluding Agents and their Effects on Embolised
541 Tissues *Curr. Vasc. Pharmacol.* **7** 250–63

542 [57] Hynynen K, Colucci V, Chung A and Jolesz F 1996 Noninvasive arterial occlusion
543 using MRI-guided focused ultrasound *Ultrasound Med. Biol* **22** 1071–7

